Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

Investors may react cautiously to news that J. B. Chemicals & Pharmaceuticals Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 27.398748
debtToEquity 0.812000
earningsGrowth 0.142000
revenueGrowth 0.089000
grossMargins 0.660190
operatingMargins 0.236000
trailingEps 43.200000
forwardEps 0.000000

J. B. Chemicals & Pharmaceuticals Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
J. B. Chemicals & Pharmaceuticals Limited's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited's price projections have been revised downward gradually, suggesting that expectations for the company's future performance are becoming more conservative. Analysts may be tempering their optimism based on current trends.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


60 JBCHEPHARM stock sales were completed, with market price of 1766.9875040690104.During the period under consideration, no sell transactions took place.The higher volume of buys compared to sells near current JBCHEPHARM price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


J. B. Chemicals & Pharmaceuticals Limited has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view J. B. Chemicals & Pharmaceuticals Limited as a reliable choice for their money, offering a promising avenue for future growth and financial gains.